| Drug Name |
Certolizumab pegol |
| Drug ID |
BADD_D00416 |
| Description |
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.[A176606]
Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_.[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L4894] and updated for a new indication on March 28, 2019.[L5819] |
| Indications and Usage |
Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA). |
| Marketing Status |
Prescription |
| ATC Code |
L04AB05 |
| DrugBank ID |
DB08904
|
| KEGG ID |
D03441
|
| MeSH ID |
D000068582
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
28877-7300; 49187-0228; 68225-045; 28877-7100; 50474-700; 50474-710 |
| Synonyms |
Certolizumab Pegol | Cimzia | CDP870 | CDP 870 |
